Literature DB >> 6339126

Impaired opsonization by serum from patients with chronic liver disease.

R J Wyke, I A Rajkovic, R Williams.   

Abstract

Serum opsonization of two organisms, E. coli and yeasts (S. cerivisiae), was examined in 68 patients with chronic liver disease (CLD). Impaired opsonization for yeasts was found in seven (29%) of 24 patients with chronic active hepatitis, six (27%) of 22 with alcoholic cirrhosis and five (23%) of 22 with primary biliary cirrhosis. Opsonization for E. coli was normal in patients with primary biliary cirrhosis but impaired in seven (29%) patients with chronic active hepatitis and three (14%) of those with alcoholic cirrhosis. The defect of opsonization in chronic active hepatitis was found mainly in patients with histological evidence of active disease. A deficiency, rather than antagonism or inhibition, of normal opsonization factors was responsible, but could not be related to reduced levels of serum complement factors of either the classical or the alternative pathway present in 45% of the patients with chronic active hepatitis, 71% with alcoholic cirrhosis and 18% of those with primary biliary cirrhosis. Serum from two of 11 patients with impaired opsonization antagonised the function of normal polymorphonuclear leucocytes, and polymorphonuclear leucocytes from six of seven patients had slightly reduced phagocytosis/killing of E. coli opsonized in normal serum. Defects of serum opsonization, complement activity and polymorphonuclear leucocyte function may be causes of the increased susceptibility to bacterial infection in patients with CLD.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339126      PMCID: PMC1536747     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  A defect of the alternative pathway of complement.

Authors:  J F Soothill; B A Harvey
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

2.  Phagocytosis as a surface phenomenon. II. Contact angles and phagocytosis of encapsulated bacteria before and after opsonization by specific antiserum and complement.

Authors:  C J Van Oss; C F Gillman
Journal:  J Reticuloendothel Soc       Date:  1972-11

3.  Homozygous deficiency of C3 in a patient with repeated infections.

Authors:  C A Alper; H R Colten; F S Rosen; A R Rabson; G M Macnab; J S Gear
Journal:  Lancet       Date:  1972-12-02       Impact factor: 79.321

4.  Complement and liver cell function in 53 patients with liver disease.

Authors:  O Kourilsky; C Leroy; A P Peltier
Journal:  Am J Med       Date:  1973-12       Impact factor: 4.965

5.  Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation.

Authors:  A Martin; P J Lachmann; L Halbwachs; M J Hobart
Journal:  Immunochemistry       Date:  1976-04

6.  [Serum secretory IgA in liver diseases and various other disorders (author's transl)].

Authors:  S Iscaki; C Buffet; M J Briantais; C Geneste; J P Etienne; J Pillot
Journal:  Gastroenterol Clin Biol       Date:  1981-03

7.  Bacteraemia in association with hepatocellular and hepatobiliary disease.

Authors:  E A Jones; S Sherlock; N Crowley
Journal:  Postgrad Med J       Date:  1967-03       Impact factor: 2.401

8.  In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood.

Authors:  P G Quie; J G White; B Holmes; R A Good
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

9.  Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure.

Authors:  R J Wyke; I A Rajkovic; A L Eddleston; R Williams
Journal:  Gut       Date:  1980-08       Impact factor: 23.059

10.  Suppression of leukocyte chemotaxis by human IgA myeloma components.

Authors:  D E Van Epps; R C Williams
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

View more
  13 in total

Review 1.  Infections.

Authors:  N Rolando; R J Wyke
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 2.  Spontaneous group B streptococcal meningitis in a patient with cirrhosis.

Authors:  B Y Tung; K V Kowdley
Journal:  West J Med       Date:  1996-10

Review 3.  Problems of bacterial infection in patients with liver disease.

Authors:  R J Wyke
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

4.  Suboptimal C3b/C3bi deposition and defective yeast opsonization. I. Evidence for the absence of essential co-factor activity.

Authors:  M W Turner; N D Seymour; M D Kazatchkine; J F Mowbray
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

5.  Early diagnosis of bacterial and fungal infection in chronic cholestatic hepatitis B.

Authors:  Xiong-Zhi Wu; Dan Chen; Lian-San Zhao; Xiao-Hui Yu; Mei Wei; Yan Zhao; Qing Fang; Qian Xu
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

6.  Decreased production of active oxygen species by neutrophils in patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  K Itoh; A Nakao; W Kishimoto; T Itoh; A Harada; T Nonami; M Nakano; H Takagi
Journal:  Gastroenterol Jpn       Date:  1993-08

7.  Functions of granulocytes and monocytes in primary biliary and alcoholic cirrhosis.

Authors:  A Blussé van Oud; A R Janssens; P C Leijh; R van Furth
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

8.  Pneumatosis intestinalis and necrotizing enterocolitis associated with liver cirrhosis.

Authors:  Y Tameda; M Hamada; T Hamaguchi; K Sugimoto; H Katou; S Nakazawa; K Takase
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

9.  Opsonization of yeast by human serum IgA anti-mannan antibodies and phagocytosis by human polymorphonuclear leucocytes.

Authors:  G R Yeaman; M A Kerr
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

Review 10.  Mammalian lectins in activation and clearance mechanisms involving the complement system.

Authors:  K B Reid; M W Turner
Journal:  Springer Semin Immunopathol       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.